Sort
130,381 grants matching “hiv”
Role of Oxidative Stress and Inflammation in HIV Cardiovascular Risk
$890,691Cecilia M Shikuma · University Of Hawaii At Manoa · R01 · FY2012 · HL
Role of Oxidative Stress and Inflammation in HIV Cardiovascular Risk
$890,587Cecilia M Shikuma · University Of Hawaii At Manoa · R01 · FY2010 · HL
Rapid Portable HIV Detection and Monitoring System for Low Resource Settings
$890,573Joel W. Grover · Thermal Gradient, Inc. · R44 · FY2012 · AI
A Bioresorbable Subdermal Implant for Sustained Delivery of a Novel Maturation Inhibitor to Prevent HIV Infection
$890,560John A Moss · Oak Crest Institute Of Science · R01 · FY2023 · AI
PHILADELPHIA PEDIATRIC AIDS CLINICAL TRIALS UNIT
$890,498Children'S Hospital Of Philadelphia · U01 · FY2001 · AI
The Study of HIV Infection in the Etiology of Lung Disease (SHIELD)
$890,479Gregory D Kirk · Johns Hopkins University · R01 · FY2008 · HL
Defining Drivers of HPV-associated Carcinogenesis
$890,460Paul F Lambert · University Of Wisconsin-Madison · R35 · FY2019 · CA
Developing Immunogens to Elicit Broadly Neutralizing anti-HIV-1 Antibodies
$890,425Pamela J Bjorkman · California Institute Of Technology · P01 · FY2024 · AI
Core 1 - Structural Biology Core
$890,349Priyamvada Acharya · Duke University · U54 · FY2022 · AI
Combined cytokine therapy for sustained HIV remission
$890,185Vijayakumar Velu · Emory University · R01 · FY2021 · AI
Kinetics, evolution, and effector function of Fc repertoires during vaccination with native-like Env trimers
$890,180D. Noah Sather · Seattle Children'S Hospital · R01 · FY2021 · AI
Kinetics, evolution, and effector function of Fc repertoires during vaccination with native-like Env trimers
$890,180D. Noah Sather · Seattle Children'S Hospital · R01 · FY2020 · AI
Administrative, Clinical and Biostatistics Core
$890,171Marcus Altfeld · Massachusetts General Hospital · P01 · FY2011 · AI
Perturbation of antigen-specific T cell responses in latent TB/SIV co-infection
$890,058Deepak Kaushal · Texas Biomedical Research Institute · R01 · FY2019 · AI
POLYCOMB REPRESSIVE COMLEXE AS KEY REGULATORS OF HIV LATENCY AND TARGETS FOR LATENCY REVERSAL
$890,017Lindsey Ingerman James · Univ Of North Carolina Chapel Hill · R61 · FY2020 · DA
POLYCOMB REPRESSIVE COMLEXE AS KEY REGULATORS OF HIV LATENCY AND TARGETS FOR LATENCY REVERSAL
$890,017Lindsey Ingerman James · Univ Of North Carolina Chapel Hill · R61 · FY2019 · DA
GH11-1154, S. Africa: PROPOSAL TO CONDUCT SURVEY DETERMINE IMPACT OF HIV PREVENTION BIOMED INTERVENTION
$890,000Cherie Anne Cawood · Epicentre Aids Risk Mgmt (Pty), Ltd · U2G · FY2015 · GH
Impact of Cannabis on Inflammation and Viral Persistence in Treated HIV/SIV
$890,000Nichole Rose Klatt · University Of Washington · DP1 · FY2015 · DA
Monthly Antiretroviral Therapy Using Multispecific HIV Neutralizing Antibodies
$890,000David D Ho · Aaron Diamond Aids Research Center · DP1 · FY2014 · DA
Monthly Antiretroviral Therapy Using Multispecific HIV Neutralizing Antibodies
$890,000David D Ho · Aaron Diamond Aids Research Center · DP1 · FY2012 · DA
Monthly Antiretroviral Therapy Using Multispecific HIV Neutralizing Antibodies
$890,000David D Ho · Aaron Diamond Aids Research Center · DP1 · FY2011 · DA
Impact of Cannabis on Inflammation and Viral Persistence in Treated HIV/SIV
$890,000Nichole Rose Klatt · University Of Washington · DP1 · FY2017 · DA
AIDS International Training and Research Program
$889,909Carey Farquhar · University Of Washington · D43 · FY2009 · TW
The Study of HIV Infection in the Etiology of Lung Disease (SHIELD)
$889,680Gregory D Kirk · Johns Hopkins University · R01 · FY2009 · HL
A Clinical Trial of Three Broadly Neutralizing Antibodies and Analytic Treatment Interruption in Early-Treated Children in Botswana
$889,638Roger L Shapiro · Harvard University D/B/A Harvard School Of Public Health · U01 · FY2025 · AI